European Journal of Medicinal Chemistry p. 1 - 9 (2013)
Update date:2022-08-03
Topics:
Sun, Jian
Lv, Xian-Hai
Qiu, Han-Yue
Wang, Yan-Ting
Du, Qian-Ru
Li, Dong-Dong
Yang, Yong-Hua
Zhu, Hai-Liang
It was discovered that a number of cyclin dependent kinase inhibitors containing the pyrazole core structure exhibited high inhibitory potency against broad-range CDKs and corresponding anti-proliferative activities. This information guided us to design and synthesize a series of 1,3-diphenyl-N- (phenylcarbamothioyl)-1H-pyrazole-4-carboxamide derivatives (5a-10d), and evaluate their biological activities as CDKs inhibitors. Among all the synthesized compounds, compound 10b inhibited CDK2 with an IC50 value of 25 nM, counteracting tumor cell proliferation of three cancer cell lines (H460, MCF-7, A549) in the micromolar range (from 0.75 μM to 4.21 μM), In addition, flow cytometry indicated that compound 10b could induce cycle G 0/G1 phase arrest in A549 cells with a dose dependent. Taken together, compound 10b could be selected for further preclinical evaluation.
View MoreNanjing Zelang Medical Technology Co. Ltd
Contact:86-25-83063290/13770714480
Address:Ganjiabian 108# 01 Unit,701-702 room,Yao Hua Street,Qixia District,Nanjing,Jiangsu,China
Contact:+0086-21-61984905-1
Address:Building 60,Zimian Park, LongYang industrial Area, 1515Nong,Yuandong Road Fengxian District, Shanghai ,China
Beijing Harmony Chemical Co., Ltd.
Contact:86-010-84956928
Address:Room 207, Jin feng he B building, No 8 Xin Jie Kou Wai Street, Xi Cheng District, Beijing,PRC. 10008
Ji'nan Orgachem Pharmaceutical Co.,Ltd
Contact:+86-531-82687810
Address:Jinan
Contact:86-0796-8187704 18507063190
Address:ji'an jiangxi
Doi:10.1039/b101723n
(2001)Doi:10.1021/acs.biochem.7b00194
(2017)Doi:10.1021/jo00944a056
(1973)Doi:10.1021/jm00276a036
(1972)Doi:10.1021/jo00944a017
(1973)Doi:10.1007/BF00487472
()